Do sudden gains predict treatment outcome in social anxiety disorder? Findings from two randomized controlled trials

Behav Res Ther. 2019 Oct:121:103453. doi: 10.1016/j.brat.2019.103453. Epub 2019 Aug 9.

Abstract

Objective: Sudden gains (SGs) have been found to occur during randomized controlled trials (RCTs) for social anxiety disorder (SAD). Evidence is mixed whether SGs relate to treatment outcome in SAD. We examined SGs in two RCTs for SAD.

Method: Study 1 (N = 68) examined SGs in individual cognitive-behavioral therapy (CBT), and Study 2 (N = 100) compared SGs in group CBT and Mindfulness-Based Stress Reduction (MBSR). Weekly ratings of social anxiety were used to calculate SGs. The Liebowitz Social Anxiety Scale-Self-Report and the Social Interaction Anxiety Scale were completed at pretreatment, posttreatment, and follow-up to assess outcome.

Results: In Study 1, 17.6% of participants experienced a SG. Participants with SGs started and ended treatment with lower social anxiety. SGs were not associated with greater decreases in social anxiety from pre-to posttreatment or 12-month follow-up. In Study 2, SGs occurred in 27% of participants and at comparable rates in MBSR and group CBT. SGs were not associated with changes in social anxiety during treatment in either condition.

Conclusion: SGs occurred during treatment for SAD. In both RCTs, participants improved regardless of experiencing a SG, suggesting that SGs are not predictive of greater improvement during treatment for SAD.

Trial registration: ClinicalTrials.gov NCT00380731 NCT02036658.

Keywords: Cognitive behavioral therapy; Mindfulness-based stress reduction; Social anxiety; Sudden gains.

Publication types

  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Cognitive Behavioral Therapy*
  • Female
  • Humans
  • Male
  • Mindfulness*
  • Phobia, Social / psychology
  • Phobia, Social / therapy*
  • Psychotherapy, Group
  • Treatment Outcome
  • Young Adult

Associated data

  • ClinicalTrials.gov/NCT00380731
  • ClinicalTrials.gov/NCT02036658